In this work, when we integrated IDH results with the intermediate risk cytogenetics, we remarkably found that the OS of the intermediate risk AML group was inferior for mutant IDH patients in comparison with wild IDH patients (median OS 1.8 years vs. 6.4 years, respectively p > 0.05). The gene discussed is IDH2; the disease is acute myeloid leukemia.